Eascra Biotech names former AbbVie exec as CSO

Eascra Biotech, a nanomedicine start-up with a laboratory in Worcester, Massachusetts, USA, has appointed Dr Andrew Goodearl, as chief scientific officer (CSO).

Dr Goodearl brings over three decades of biopharmaceutical experience to the role, which will focus on advancing Eascra’s commercialization strategy and accelerating product development. Eascra noted that his career has been dedicated to advancing biotherapeutic candidates from discovery through to clinical stages. His expertise covers a broad range of therapeutic areas, including immunology, neuroscience, ophthalmology, renal disease, oncology, and virology.